These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 8333073

  • 21. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
    Purighalla R, Shapiro R, Jordan ML, Scantlebury VP, Gritsch HA, Vivas C, Randhawa PS.
    Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
    [Abstract] [Full Text] [Related]

  • 22. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM, Angel L, Anzueto A, Susanto I, Peters JI, Sako EY, Bryan CL.
    Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
    [Abstract] [Full Text] [Related]

  • 23. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 24. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R, Novick AC, Hodge E, Goormastic M, Papajcik D, Mastroianni B, Cook D.
    Urology; 1996 Jun 15; 47(6):807-12. PubMed ID: 8677568
    [Abstract] [Full Text] [Related]

  • 25. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 26. Course of renal allograft function after diagnosis and treatment of post-transplant lymphoproliferative disorders in pediatric kidney transplant recipients.
    Zierhut H, Kanzelmeyer N, Buescher A, Höcker B, Mauz-Körholz C, Tönshoff B, Metzler M, Pohl M, Pape L, Maecker-Kolhoff B.
    Pediatr Transplant; 2021 Sep 27; 25(6):e14042. PubMed ID: 34021949
    [Abstract] [Full Text] [Related]

  • 27. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R, Ben Shalom E, Landau D, Weissman I, Krause I, Konen O, Rahamimov R, Mor E, Bar-Nathan N, Frishberg Y, Davidovits M.
    Pediatr Transplant; 2012 Sep 27; 16(6):619-26. PubMed ID: 22708682
    [Abstract] [Full Text] [Related]

  • 28. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 29. Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.
    Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DE, Najarian JS.
    Transplantation; 1992 Jul 15; 54(1):50-6. PubMed ID: 1631944
    [Abstract] [Full Text] [Related]

  • 30. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
    McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, Jevnikar AM, Rizkalla KS.
    Liver Transpl; 2000 Sep 15; 6(5):570-4. PubMed ID: 10980055
    [Abstract] [Full Text] [Related]

  • 31. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder.
    Alfrey EJ, Friedman AL, Grossman RA, Perloff LJ, Naji A, Barker CF, Montone KT, Tomaszewski JE, Chmielewski C, Holland T.
    Transplantation; 1992 Aug 15; 54(2):250-3. PubMed ID: 1323150
    [Abstract] [Full Text] [Related]

  • 32. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr 15; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 33. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M, Latter DA, Loertscher R.
    Clin Transplant; 1997 Aug 15; 11(4):316-21. PubMed ID: 9267721
    [Abstract] [Full Text] [Related]

  • 34. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA, Hamilton-Dutoit S.
    Transplantation; 2003 Sep 27; 76(6):984-8. PubMed ID: 14508366
    [Abstract] [Full Text] [Related]

  • 35. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun 27; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 36. Predicting factors for long-term results of OKT3 therapy in steroid-resistant acute rejection following cadaveric renal transplantation.
    Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D.
    Transplant Proc; 1998 Jun 27; 30(4):1170-2. PubMed ID: 9636473
    [No Abstract] [Full Text] [Related]

  • 37. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep 27; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 38. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
    Brennan DC, Schnitzler MA, Baty JD, Ceriotti CS, Lowell JA, Shenoy S, Howard TK, Woodward RS.
    Pharmacoeconomics; 1997 Mar 27; 11(3):237-45. PubMed ID: 10165313
    [Abstract] [Full Text] [Related]

  • 39. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ, Jordan SC, Nathan SD, Kass RM, Koerner SK.
    Chest; 1996 Apr 27; 109(4):870-3. PubMed ID: 8635362
    [Abstract] [Full Text] [Related]

  • 40. Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update.
    Hertig A, Zuckermann A.
    Transpl Immunol; 2015 Jun 27; 32(3):179-87. PubMed ID: 25936966
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.